Total Payments
$226,114
2024 Payments
$107,059
Companies
26
Transactions
146
Payment Breakdown by Category
Research$191,268 (84.6%)
Other$21,482 (9.5%)
Consulting$10,750 (4.8%)
Food & Beverage$1,958 (0.9%)
Travel$642.43 (0.3%)
Education$12.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $191,268 | 49 | 84.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,482 | 13 | 9.5% |
| Consulting Fee | $10,750 | 2 | 4.8% |
| Food and Beverage | $1,958 | 79 | 0.9% |
| Travel and Lodging | $642.43 | 2 | 0.3% |
| Education | $12.29 | 1 | 0.0% |
Payments by Type
Research
$191,268
49 transactions
General
$34,845
97 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IGI Inc | $106,841 | 30 | $0 (2024) |
| Ichnos Sciences Inc. | $68,433 | 11 | $0 (2023) |
| F. Hoffmann-La Roche AG | $11,457 | 8 | $0 (2021) |
| Terumo BCT, Inc. | $10,997 | 7 | $0 (2020) |
| MacroGenics, Inc. | $9,954 | 3 | $0 (2021) |
| Genentech USA, Inc. | $8,888 | 33 | $0 (2019) |
| Incyte Corporation | $5,446 | 5 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $2,876 | 9 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $341.75 | 8 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $273.59 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107,059 | 33 | IGI Inc ($106,841) |
| 2023 | $68,449 | 12 | Ichnos Sciences Inc. ($68,433) |
| 2022 | $11.66 | 1 | EMD Serono, Inc. ($11.66) |
| 2021 | $13,669 | 5 | MacroGenics, Inc. ($9,954) |
| 2020 | $15,809 | 10 | Terumo BCT, Inc. ($10,948) |
| 2019 | $2,536 | 8 | F. Hoffmann-La Roche AG ($2,280) |
| 2018 | $5,607 | 28 | Incyte Corporation ($2,792) |
| 2017 | $12,974 | 49 | Genentech USA, Inc. ($8,723) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | IGI Inc | — | — | Cash or cash equivalent | $4,542.00 | Research |
| Study: GRC 54276-101 | ||||||
| 12/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,280.00 | Research |
| Study: GRC 54276-101 | ||||||
| 12/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,736.00 | Research |
| Study: GRC 54276-101 | ||||||
| 12/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $609.00 | Research |
| Study: GRC 54276-101 | ||||||
| 12/13/2024 | IGI Inc | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: GRC 54276-101 | ||||||
| 09/25/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,339.74 | Research |
| Study: GRC 54276-101 | ||||||
| 09/20/2024 | IGI Inc | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: GRC 54276-101 | ||||||
| 09/18/2024 | IGI Inc | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: GRC 54276-101 | ||||||
| 09/18/2024 | IGI Inc | — | — | Cash or cash equivalent | $400.00 | Research |
| Study: GRC 54276-101 | ||||||
| 08/02/2024 | IGI Inc | — | — | Cash or cash equivalent | $609.00 | Research |
| Study: GRC 54276-101 | ||||||
| 07/10/2024 | IGI Inc | — | — | Cash or cash equivalent | $28,164.00 | Research |
| Study: GRC 54276-101 | ||||||
| 07/10/2024 | IGI Inc | — | — | Cash or cash equivalent | $9,556.00 | Research |
| Study: GRC 54276-101 | ||||||
| 07/10/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,280.00 | Research |
| Study: GRC 54276-101 | ||||||
| 06/21/2024 | IGI Inc | — | — | Cash or cash equivalent | $903.00 | Research |
| Study: GRC 54276-101 | ||||||
| 06/07/2024 | IGI Inc | — | — | Cash or cash equivalent | $905.80 | Research |
| Study: GRC 54276-101 | ||||||
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $87.61 | Research |
| Study: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ||||||
| 05/31/2024 | ABBVIE INC. | — | — | In-kind items and services | $41.72 | Research |
| Study: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ||||||
| 05/24/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,067.40 | Research |
| Study: GRC 54276-101 | ||||||
| 05/24/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,412.64 | Research |
| Study: GRC 54276-101 | ||||||
| 05/24/2024 | IGI Inc | — | — | Cash or cash equivalent | $418.00 | Research |
| Study: GRC 54276-101 | ||||||
| 05/22/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $88.99 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | IGI Inc | — | — | Cash or cash equivalent | $872.00 | Research |
| Study: GRC 54276-101 | ||||||
| 04/17/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,256.00 | Research |
| Study: GRC 54276-101 | ||||||
| 04/10/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,279.80 | Research |
| Study: GRC 54276-101 | ||||||
| 04/05/2024 | IGI Inc | — | — | Cash or cash equivalent | $2,107.00 | Research |
| Study: GRC 54276-101 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GRC 54276-101 | IGI Inc | $106,841 | 30 |
| GRC 54276-101 | Ichnos Sciences Inc. | $68,433 | 11 |
| MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS | MacroGenics, Inc. | $9,954 | 3 |
| A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB MPDL3280A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR HEMATOLOGIC MALIGNANCIES | F. Hoffmann-La Roche AG | $2,990 | 2 |
| A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED WITH BEVACIZUMAB ANDOR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS | F. Hoffmann-La Roche AG | $2,921 | 1 |
| A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors | ABBVIE INC. | $129.33 | 2 |
About Dr. John Powderly, M.D
Dr. John Powderly, M.D is a Hematology & Oncology healthcare provider based in Huntersville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265453047.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Powderly, M.D has received a total of $226,114 in payments from pharmaceutical and medical device companies, with $107,059 received in 2024. These payments were reported across 146 transactions from 26 companies. The most common payment nature is "" ($191,268).
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Huntersville, NC
- Active Since 07/21/2006
- Last Updated 07/10/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1265453047
Products in Payments
- TECENTRIQ (Biological) $15,254
- Tecentriq (Biological) $4,835
- KEYTRUDA (Biological) $2,833
- OPDIVO (Biological) $341.75
- Quantum Cell Expansion System (Device) $267.78
- IMFINZI (Drug) $215.64
- Avastin (Biological) $105.05
- Reveos Automated Blood Processing System (Device) $100.97
- ALUNBRIG (Drug) $88.99
- Perjeta (Biological) $82.31
- BENDEKA (Drug) $50.20
- Spectra Optia (Device) $48.60
- Spectra Optia Apheresis System (Device) $47.63
- TAGRISSO (Drug) $44.92
- Alecensa (Biological) $28.23
- SYNDROS (Drug) $24.32
- SUBSYS (Drug) $22.26
- XTANDI (Drug) $17.16
- Gelclair (Device) $16.98
- Rituxan (Biological) $16.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Huntersville
Jack Burton
Hematology & Oncology — Payments: $27,900
Hematology & Oncology $27,900
Timothy Kuo, Md, MD
Hematology & Oncology — Payments: $1,192
Hematology & Oncology $1,192
Jia Hao Liang, Md, MD
Hematology & Oncology — Payments: $795.66
Hematology & Oncology $795.66
Dr. Karim Tazi, Md, MD
Hematology & Oncology — Payments: $493.29
Hematology & Oncology $493.29